Daiichi-Sankyo
Information
Our company was founded in 2006 through the merger of the well-established Japanese companies Daiichi and Sankyo in Europe. Daiichi Sankyo is a global pharmaceutical company based in Japan that has a presence in more than 20 countries around the world. With a rich legacy of over 100 years of scientific expertise, we are the pioneer behind leading pharmaceuticals that have contributed to the improvement of countless lives. Our global headquarters is in Tokyo. In Europe, we have affiliates in 13 countries with about 1,500 employees. Our European headquarters is in Munich, Germany, and not far from there, one of our global production plants is located in Pfaffenhofen.
Our company's roots in Europe go back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. In 1990 Sankyo acquired the Luitpold Werke in Munich, Germany, a mid-sized German pharmaceutical company with production facilities in Pfaffenhofen, Germany and Altkirch, France. In 2006, the merger between the two Japanese companies took place in Europe. Today our European headquarters are located in Munich. We currently do business in 13 European countries. Through licensing and sales agreements, our
products are available in almost every European market as well as in more than
50 countries outside the EU.
With about 1,500 employees, we are one of the strongest Japanese pharmaceutical companies in Europe.
We strive to help patients with cardiovascular diseases by developing innovative treatments. Since 2002 our cardiovascular treatments have improved outcomes of over 40 million* patients across Europe.”
We are the pioneer behind leading pharmaceuticals such as
- Adrenalin (an adrenal cortex hormone agent that became the first blockbuster medicine of the 20th century)
- Pravastatin (a globally groundbreaking anti-hyperlipidemic agent)
Our current cardiovascular portfolio includes products for
- Atrial fibrillation
- Hypertension
- Thrombotic disorders
*40 million patients treated with olmesartan and its combinations, prasugrel, edoxaban, pravastatin in selected countries